Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding the vesting of conditional share awards under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics and Performance Targets
The filing details specific performance metrics used to determine share award vesting rather than reporting full-period financial statements.
- Adjusted Free Cash Flow Target: The company achieved a target of £17.4 billion over the three-year period (January 1, 2009, to December 31, 2011), exceeding the required target of £16 billion.
- Total Shareholder Return (TSR): For the three-year period, GSK ranked 6th (median position) against a comparator group of 11 pharmaceutical companies.
- Share Price: The closing middle market price of an Ordinary share on February 17, 2012, was £14.14.
Material Changes and Vesting Outcomes
The vesting of the 2009 Performance Share Plan awards was contingent on the metrics above. The outcomes for the three-year performance period were as follows:
- Free Cash Flow Element (40% of award): 100% of this element vested due to exceeding the cash flow target.
- TSR Element (60% of award):
- Three-Year Portion (30% of total award): Only 30% of this portion vested (representing 9% of the total award) due to median TSR ranking. The balance of this portion lapsed.
- Four-Year Portion (30% of total award): Remains outstanding and will be measured in February 2013.
- Total Vesting: 49% of the total award vested, while 21% lapsed. The remaining 30% is subject to the four-year performance period ending December 31, 2012.
Management Commentary and Risks
The Remuneration Committee confirmed the vesting percentages based on the performance conditions. The filing notes that the four-year TSR element remains contingent on future performance through the end of 2012. No specific risks or contingencies regarding the company's general operations were disclosed in this specific notification, as the document focuses solely on executive compensation mechanics.
Investor Verification Checklist
- Verify the final vesting calculation for the four-year TSR element in February 2013.
- Confirm the specific number of shares vested and lapsed for Executive Directors (Sir Andrew Witty and Dr M Slaoui) versus other PDMRs.
- Review the full 2011 annual report to contextualize the £17.4 billion adjusted free cash flow figure against broader financial results.
- Check subsequent filings for the outcome of the four-year TSR performance period.